Menopause care beyond HRT: what UK telehealth services should offer when hormones aren't the answer

Most UK menopause telehealth services are built around one product: HRT. That works for the majority of patients, but it leaves a gap for everyone else, the patient with a personal or family breast cancer history, the one who tried patches and stopped, the one who simply doesn't want hormones. A service with no answer for that group either loses them at triage or, worse, keeps pushing HRT past the point it's clinically or personally appropriate.

Why a single-product menopause pathway breaks down

HRT is the most effective treatment for vasomotor symptoms for most patients, and it's reasonable that it sits at the centre of a menopause service's clinical model. The problem is what happens to the patients who fall outside that fit: contraindications such as a personal history of hormone-sensitive breast cancer, unprovoked VTE, or active liver disease, plus the smaller group who are eligible but decline it after trying it, or on principle.

A service without a clear non-hormonal pathway tends to handle these patients one of two ways, both poor: signposting them out with no further support, or continuing to frame every consultation around HRT until the patient disengages. Neither builds retention, and the second carries a safety-netting problem if it edges toward pressuring an unwilling or contraindicated patient.

What NICE NG23 actually sets out for non-hormonal management

NICE's menopause guideline (NG23) is explicit that non-hormonal options exist and should be discussed, not treated as a fallback mentioned only when a patient objects. For vasomotor symptoms specifically, it names SSRIs and SNRIs (prescribed off-label for this indication, which needs to be explained to the patient as part of consent) and clonidine as pharmacological options, alongside cognitive behavioural therapy (CBT), which NICE notes can help with vasomotor symptoms, low mood, and sleep disruption even though it doesn't reduce symptom frequency the way medication can.

None of this requires inventing a new clinical model. It requires the prescriber having somewhere to go in the consultation, and the service having the workflow and consent documentation to support a prescription that's clearly off-label, with the discussion recorded and prescriber discretion applied throughout.

The testosterone question, and why it's a different conversation

Testosterone for low libido in menopause comes up often enough in patient searches and forums that a service needs a considered position on it, not silence. The practical position: testosterone isn't licensed for this indication in the UK, prescribing it is an off-label, specialist-initiated decision (typically endorsed by British Menopause Society guidance), and it sits outside what a general remote menopause service should be initiating without the relevant prescriber experience and monitoring pathway (baseline and follow-up levels, response review) in place.

Where a service doesn't have that specialist capability, the honest answer is a clear referral pathway, not a quiet decline to discuss it, and not an unsupported prescription. Patients notice the difference between "we don't do that here, but here's where to go" and being brushed off.

Building the contraindication and preference workflow

• Capture personal and family history (hormone-sensitive cancers, VTE, liver disease) at triage, not buried in a free-text field the prescriber has to hunt for
• Flag automatically when a patient's history rules out standard HRT routes, and route the consultation toward the non-hormonal pathway by default
• Give the prescriber a structured way to record "HRT declined by patient preference" separately from "HRT contraindicated", since the follow-up and documentation needs differ
• Set a review interval for non-hormonal prescriptions (SSRIs/SNRIs, clonidine) that matches their different titration and side-effect profile, not the standard HRT review cadence
• Keep a live, checked referral list for testosterone and specialist menopause clinics, not a static link that goes stale

Consent and documentation for off-label prescribing

Off-label use is common and legitimate in menopause care, but it needs to be visibly handled that way. The consultation record should show that the off-label status was explained, that the patient understood the alternative was licensed HRT (where eligible), and that the decision was the patient's own, reached with prescriber discretion applied. This is the kind of documentation a CQC inspection or a complaint investigation will look for specifically.

It's also worth building the same discipline into patient-facing content: FAQ and product pages that mention SSRIs or clonidine for menopause should say plainly that this is an off-label use of a licensed medicine, not imply it's a dedicated menopause treatment.

The patients who fall outside the HRT-eligible majority aren't an edge case to route around. They're the group that tells you whether your clinical model actually holds up.

What this costs to build, and what it protects

None of this is expensive relative to a typical clinic build. It's mostly triage logic, a prescriber decision tree, and a referral list that someone actually maintains. What it protects is retention among a meaningful minority of the menopause patient base, and it closes a safety-netting gap that a single-product model leaves open by default.

Services that treat this as core clinical design, not an edge case, tend to see it show up as fewer abandoned consultations and fewer complaints about feeling dismissed, rather than as a measurable revenue line on its own.

Where PExpo fits

PExpo's dispensing layer handles the mechanics that sit underneath a broader menopause pathway: off-label prescriptions dispensed and labelled correctly, clear records for CQC and GPhC purposes, and the same operational reliability whether the item is an HRT patch or an SSRI prescribed for vasomotor symptoms. That consistency matters more once a clinic is running two prescribing pathways instead of one.

See how it fits alongside an existing women's-health vertical or a standalone HRT service on the clinics page.

A resilient menopause offering isn't one product with exceptions bolted on. It's a triage and prescribing workflow built for both the HRT majority and the patients who can't or won't take it, backed by documentation that shows the decision was theirs. For the operational side of running that alongside HRT prescribing, see how PExpo's dispensing layer supports both pathways from one clinic build, and how it compares in a broader women's-health vertical.

Frequently asked questions